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Defective negative regulation of antigen receptor signaling in
Lyn-deficient B lymphocytes
Vivien W.F. Chan*†, Clifford A. Lowell† and Anthony L. DeFranco*‡§
Background: To elucidate the role of the Src family kinase Lyn in B cell
receptor (BCR) signaling, we and others previously generated lyn–/– mice and
analyzed their B cell responses. Although the initiation of BCR signaling in
lyn–/– B cells is delayed, BCR-induced ERK2 activation and proliferation are
enhanced. As the co-receptors FcγRIIb1 and CD22 have been shown to be
negative regulators of BCR signaling, we have now examined their functional
roles in lyn–/– B cells.
Results: B cells from lyn–/– mice have increased expression of the protein
product of the early response gene egr-1, enhanced activation of Jun N-terminal
kinase (JNK), and elevated calcium responses upon BCR cross-linking. Tyrosine
phosphorylation of FcγRIIb1 in lyn–/– B cells was reduced but negative
regulation of the BCR signal by FcγRIIb1 was only modestly impaired. In
contrast, tyrosine phosphorylation of CD22 was greatly decreased in lyn–/– B
cells, correlating with the inability of CD22 to downregulate the BCR-induced
calcium response in these cells. Surprisingly, CD22 remains capable of
regulating the ERK2 and JNK pathways in lyn–/– B cells, which may relate to the
small residual increase in BCR-induced CD22 phosphorylation.
Conclusions: BCR signal initiation and negative regulation by FcγRIIb1 is not
critically dependent on Lyn. In contrast, Lyn plays a particularly important role in
the tyrosine phosphorylation of CD22 and in the consequent inhibition of BCR-
induced calcium influx. The net result of the Lyn deficiency in B cells is
hyperresponsiveness to antigen stimulation, which may explain the
autoimmunity observed in lyn–/– mice.
Background
B cell receptor (BCR) engagement leads to the activation
of the tyrosine kinases Syk and Btk and of Src family tyro-
sine protein kinases. This activation results in increases in
the following cellular events: tyrosine phosphorylation of
numerous signaling proteins; phosphatidylinositol
turnover; the elevation of intracellular free calcium; and
the activation of serine/threonine kinase cascades such as
the extracellular signal-regulated kinase (ERK), Jun N-
terminal kinase (JNK) and p38 pathways [1]. The signal-
ing events triggered by the BCR can be modulated by
co-receptors such as CD19, FcγRIIb1 and CD22, which
associate with the BCR either constitutively or in a ligand-
dependent manner [2]. These factors contribute to deter-
mining whether B lymphocytes respond positively to
antigen-induced BCR signaling by proliferating or nega-
tively by undergoing anergy or apoptosis.
Co-ligation of FcγRIIb1 with the BCR, which occurs
when antigen is presented in the form of immune com-
plexes with immunoglobulin (Ig) G, results in the dephos-
phorylation of CD19 and in decreases in a range of cellular
processes: phosphatidylinositol turnover; transmembrane
calcium influx; signaling through the Ras pathway; and B
cell proliferation [3–6]. The inhibitory effects of FcγRIIb1
are dependent on a tyrosine motif in its cytoplasmic
domain which is phosphorylated upon co-ligation with the
BCR [7]. Both the inositol phosphatase SHIP and the
tyrosine phosphatase SHP-1 are recruited by FcγRIIb1
[8,9], but the inhibitory effects of FcγRIIb1 appear to be
primarily mediated by SHIP [10,11].
CD22 is another membrane protein that regulates BCR
signaling and is associated with the BCR at low stoichiom-
etry, becoming tyrosine phosphorylated and binding to
SHP-1 upon BCR engagement [12–17]. Calcium signaling
appears to be one of the BCR signaling pathways that is
negatively regulated by CD22, as B cells from mice
lacking CD22 have exaggerated calcium responses to BCR
signaling [18–21]. Other signaling events regulated by
CD22 include the activation of mitogen-activated protein
(MAP) kinase pathways, which are suppressed when
CD22 is co-ligated with the BCR signaling complex and
are enhanced when CD22 is ligated alone before BCR
engagement [22]. In addition, CD22 alone seems to
mediate a positive signal in B cells [14,23]. 
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We and others have previously shown that B cells from
lyn–/– mice exhibit a hyperproliferative response to BCR
signaling [24,25], which correlates with an enhanced acti-
vation of the Ras/ERK pathway [25] and evidence of
autoimmunity in these mice in vivo [25–27]. Here, we
demonstrate that lyn–/– B cells also have enhanced JNK
activation, as well as an increased calcium response to
BCR signaling compared with wild-type B cells. These
results suggest that one or more downregulatory signaling
pathways are dependent on Lyn. In the absence of Lyn,
the tyrosine phosphorylation of FcγRIIb1 induced by
intact anti-IgM antibody was reduced, and the tyrosine
phosphorylation of CD22 was almost completely absent.
We examined the inhibitory functions of FcγRIIb1 and
CD22 in the absence of Lyn and found that the ability of
CD22 to mediate inhibition of BCR-induced calcium sig-
naling was dramatically impaired.
Results
Enhanced activation of the ERK and JNK pathways in lyn–/–
B cells
We previously found that ERK1, ERK2 and the MAP
kinase kinase MEK1 were hyperactivated at all time
points examined after BCR engagement in lyn–/– B cells
[25]. To examine whether the BCR-induced activation of
other serine/threonine kinase pathways was also altered,
we assayed for JNK activity by an in vitro kinase assay
(Figure 1a). The activation of JNK at intermediate doses
of anti-IgM antibody was higher in lyn–/– B cells than in
wild-type B cells; this effect was also observed for ERK2
activation (Figure 1b; [25]). BCR cross-linking only weakly
activated p38 kinase and there was no significant differ-
ence between wild-type and lyn–/– B cells (data not shown).
One BCR-induced early response gene that is dependent
on the Ras/ERK pathway is egr-1 [28]. BCR-induced Egr-1
protein expression was enhanced in lyn–/– B cells
(Figure 1c), indicating that the enhanced activation of the
Ras/ERK pathway affected downstream gene induction. 
Exaggerated calcium signaling in lyn–/– B cells
The hyperproliferative phenotype and the hyperactivation
of the ERK and JNK pathways in lyn–/– B cells suggested
that Lyn is important for the mechanisms that negatively
modulate these pathways. B cells from mice that are defi-
cient for proteins involved in BCR signal downregulation,
such as FcγRIIb1, CD22 and SHP-1, all have exaggerated
calcium signaling [18–21,29,30]. We therefore examined
the calcium responses in lyn–/– B cells. A higher elevation of
intracellular calcium in lyn–/– B cells than in wild-type B
cells was observed in response to BCR cross-linking both in
the absence of FcγRIIb1 inhibition, using anti-IgM F(ab′)2
antibody fragments for stimulation (Figure 2a,b), and in the
presence of FcγRIIb1 inhibition, using intact rabbit anti-
IgM antibodies (Figure 2c,d). The difference in calcium
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Enhanced activation of JNK and ERK pathways in lyn–/– B cells by
anti-IgM stimulation. (a,b) Purified splenic B cells were treated with
media alone or goat F(ab′)2 fragments against mouse IgM at the
indicated concentrations at 37°C for 10 min. (a) JNK1/2 and (b) ERK2
activities were assayed by in vitro kinase assays using GST–c-
Jun(1–79) and GST–Elk-1 as substrates respectively. The levels of 32P
incorporation were quantitated using a PhosphorImager and
represented as relative activity with respect to the unstimulated wild-
type sample. The nitrocellulose filters were immunoblotted for JNK1/2
and ERK2 to verify equivalent loading. The slowly migrating form of
ERK2, denoted by ERK2* in (b), is the active form of ERK2. (c) Purified
splenic B cells (5 × 106 per sample) were stimulated with the indicated
concentrations of intact rabbit anti-IgM antibody or anti-IgM F(ab′)2
antibody fragments at 37°C for 1 h. Cells were washed and
subsequently lysed with SDS sample buffer. Solubilized proteins were
separated by SDS–PAGE, transferred to nitrocellulose and
immunoblotted with anti-Egr-1 antibodies. The same nitrocellulose blot
was also immunoblotted with anti-Syk antibodies to verify loading
equivalency and with anti-Lyn antibodies to demonstrate the genotype
of the cells.
response between the wild-type and lyn–/– B cells was most
obvious at intermediate doses of anti-IgM antibody.
The amplitude of the early calcium response and that of
the sustained phase of calcium elevation, representing the
transient release of calcium from intracellular stores and
transmembrane calcium influx respectively [31], were
both higher in lyn–/– B cells than in wild-type B cells
(Figure 2a,b). When cells were stimulated with anti-IgM
F(ab′)2 antibody fragments in the presence of EGTA to
deplete extracellular calcium, the calcium levels in both
wild-type and lyn–/– B cells returned to comparable, almost
baseline levels within 6 minutes of stimulation
(Figure 2f). This suggested that the higher sustained
calcium levels observed in lyn–/– B cells were primarily due
to transmembrane calcium influx (Figure 2e).
The data in Figure 2e,f also show a slightly longer delay
before the initiation of the calcium response in the lyn–/– B
cells. A delay in calcium response was consistently
observed in lyn–/– B cells over a wide range of anti-IgM
antibody doses (compare Figure 2a with 2b). We have pre-
viously reported that BCR-induced tyrosine phosphoryla-
tion of a number of substrates was also delayed in lyn–/– B
cells [25]. These results are consistent with the model that
Lyn participates in the initiation of the BCR signal in
addition to signal downregulation.
Normal surface expression of FcgRIIb1 and CD22 in lyn–/–
B cells
One possible explanation for defective downregulation of
the BCR signal would be decreased expression of
inhibitory molecules in lyn–/– B cells, such as FcγRIIb1
and CD22. The level of cell surface expression of these
two proteins was examined by flow cytometry and was
found to be identical in wild-type and lyn–/– B cells (data
not shown). 
Decreased tyrosine phosphorylation of FcgRIIb1 and CD22
To investigate the biochemical basis for the defective
negative regulation in lyn–/– B cells, we examined the tyro-
sine phosphorylation of FcγRIIb1 and CD22 after BCR
engagement. As shown in Figure 3a, tyrosine phosphoryla-
tion of FcγRIIb1 was reduced in lyn–/– B cells compared
with wild-type B cells. Nevertheless, a significant amount
of FcγRIIb1 phosphorylation in lyn–/– B cells was evident
at the higher dose of anti-IgM antibody. The kinetics of
FcγRIIb1 phosphorylation were slower in lyn–/– B cells and
the degree of phosphorylation was lower than in wild-type
B cells at all time points examined (Figure 3b).
In contrast to the modest effect of the absence of Lyn on
FcγRIIb1 phosphorylation, we observed a dramatic reduc-
tion in tyrosine phosphorylation of CD22 in lyn–/– B cells,
both in the basal phosphorylation state as well as after
stimulation with anti-IgM antibody (Figure 3c). The level
of tyrosine phosphorylation of CD22 in lyn–/– B cells was
lower at each time point and did not exceed that of the
basal state in wild-type B cells (Figure 3d).
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Figure 2
Enhanced calcium response to stimulation with anti-IgM antibody in
lyn–/– B cells. (a,c) Wild-type or (b,d) lyn–/– B cells were stimulated with
the indicated concentrations of (a,b) goat anti-IgM F(ab′)2 antibody
fragments or (c,d) intact rabbit anti-IgM antibody. The calcium responses
to 2 µM calcium ionophore A23187 are shown in (a,b), to verify equal
Fluo-3 loading. (e,f) Wild-type or lyn–/– cells were stimulated with anti-
IgM F(ab′)2 antibody fragments at 4 µg/ml in (e) the absence of 1 mM
EGTA or (f) the presence of 1 mM EGTA to chelate extracellular
calcium. Anti-IgM antibody was added at 1 min (indicated by arrow) in
each case to Fluo-3-loaded cells and analyzed by flow cytometry. The
results were representative of three or more independent experiments.
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Blocking FcgRIIb1 enhances the BCR-induced calcium
response in both wild-type and lyn–/– B cells
Given the reduction of the BCR-induced tyrosine phos-
phorylation of FcγRIIb1 and CD22, it was of interest to
investigate whether the inhibitory functions of these pro-
teins were impaired. We pretreated cells with an antibody
(2.4G2) that binds to FcγRII and prevents it from being
co-ligated with the BCR and examined the calcium
response to intact rabbit anti-IgM antibody. Pretreatment
with 2.4G2 augmented the calcium response in both wild-
type and lyn–/– B cells (Figure 4a,b). This is consistent
with our previous observation that 2.4G2 pretreatment
enhances proliferation and ERK2 activation by intact
rabbit anti-IgM antibody in lyn–/– B cells [25] and suggests
that FcγRIIb1-mediated inhibition of these events is at
least partially functional in the absence of Lyn.
Preligating CD22 enhances the BCR-induced calcium
response in wild-type but not in lyn–/– B cells
B cells from CD22–/– mice have an increased calcium
response upon BCR stimulation, suggesting that CD22
participates in the downregulation of this calcium
response [18–21]. Given the dramatic reduction in phos-
phorylation of CD22 in lyn–/– B cells, we examined
whether CD22 function was affected, using an approach
analogous to the FcγRIIb1 pre-blocking experiment
described in Figure 4a,b above. Anti-IgM F(ab′)2 antibody
fragments were used for stimulation in this and the follow-
ing series of experiments to avoid the involvement of
FcγRIIb1. Preligation of CD22 enhanced the BCR-
induced calcium response in wild-type B cells
(Figure 4c,e). When a secondary antibody was used to
further cross-link (‘super-crosslink’) the anti-CD22 
antibody before anti-IgM antibody stimulation, the result-
ing calcium response was further increased. As the preliga-
tion of CD22 and the lack of CD22 expression both
resulted in enhanced calcium responses, a probable inter-
pretation of this result is that preligation of CD22
sequesters this co-receptor away from the BCR signaling
complex and thereby prevents its inhibition of the BCR-
induced calcium response. In contrast to its effect in wild-
type B cells, CD22 preligation did not result in a
comparable enhancement of anti-IgM induced calcium
flux in lyn–/– B cells (Figure 4d,f). 
The lack of calcium signal enhancement by anti-CD22
antibody pretreatment in lyn–/– B cells was not due to
these cells having already attained a maximal level of sig-
naling, as these experiments were carried out at interme-
diate doses of anti-IgM F(ab′)2 antibody fragments for
wild-type and lyn–/– B cells as determined in Figure 2.
Note that it is possible for lyn–/– B cells to achieve calcium
responses higher than that observed in Figure 4f at higher
doses of anti-IgM antibody (Figures 4d,2b). Indeed, the
lyn–/– B cells had a defect in CD22 regulation of the BCR-
induced calcium response over a wide range of doses of
anti-IgM antibody (data not shown). Analogous experi-
ments were performed with another anti-CD22 antibody
(CY34.1) and results similar to those in Figure 4c–f were
obtained (data not shown). These experiments indicated
that the ability of CD22 to regulate calcium signaling in a
negative manner was impaired in the absence of Lyn.
CD22 regulation of ERK2 and JNK pathways
We next examined the effects of CD22 preligation on the
ERK and JNK pathways. Wild-type B cells that were
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Figure 3
Decreased tyrosine phosphorylation of
FcγRIIb1 and CD22 in lyn–/– B cells. 
(a,b) Purified wild-type or lyn–/– splenic B
cells were treated with media alone or with
the indicated concentrations of rabbit anti-IgM
antibody for 3 min (a) or with 5 µg/ml rabbit
anti-IgM antibody for the indicated times (b) at
37°C. FcγRIIb1 was immunoprecipitated from
350 µg protein lysate using protein-
G–Sepharose beads covalently conjugated to
2.4G2 antibodies and the degree of tyrosine
phosphorylation of FcγRIIb1 was analyzed by
anti-phosphotyrosine immunoblotting. The
sizes of protein markers in kDa are shown to
the left. (c,d) Purified splenic B cells were
treated with media alone or with intact rabbit
anti-IgM antibody (rabbit) or anti-IgM F(ab′)2
antibody fragments (F(ab′)2) at the indicated
concentrations for 2 min at 37°C (c) or with
12 µg/ml anti-IgM F(ab′)2 antibody fragments
for varying lengths of time (d). CD22 was
immunoprecipitated from 200 µg protein
lysate and immunoblotted with anti-
phosphotyrosine (anti-PTyr) antibodies. The
nitrocellulose filters in the upper panels were
subsequently stripped and immunoblotted for
CD22 to verify loading equivalency (lower
panels). The results are representative of
three or more independent experiments.
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treated with anti-CD22 antibodies followed by super-
crosslinking using a secondary antibody had enhanced
activation of ERK2 (Figure 5a) and JNK1/2 (Figure 5b) by
anti-IgM antibody. These results are similar to those of
previously reported experiments using biotinylated anti-
CD22 F(ab) fragments followed by avidin treatment [22].
Despite the already elevated activities of these kinases in
lyn–/– B cells compared with wild-type B cells following
stimulation with anti-IgM antibody, anti-CD22 pretreat-
ment and super-crosslinking further enhanced the ERK2
and JNK responses in lyn–/– B cells. In all the experiments
that we have performed, CD22 pretreatment consistently
led to an increase in ERK2 and JNK1/2 activities in both
wild-type and lyn–/– B cells (Table 1). In each experiment,
the fold increase in activities of these kinases after CD22
pretreatment was lower in lyn–/– B cells than in wild-type B
cells. It is possible that the ability of CD22 to negatively
regulate the ERK2 and JNK1/2 pathways was somewhat
diminished in the absence of Lyn. Alternatively, the dif-
ference in enhancement may simply reflect the fact that
BCR stimulation of lyn–/– B cells by itself caused a greater
activation of ERK2 and JNK1/2, resulting in a reduced
ability to increase this activation. Nevertheless, it is clear
that although the absence of Lyn caused a striking impair-
ment of CD22 function in the downregulation of the
calcium response, some CD22-mediated downregulation
of ERK2 and JNK pathways was still evident.
Discussion
Of the Src family tyrosine kinases, Lyn is the most highly
expressed in B cells. These kinases have historically been
regarded as signal initiators in BCR signaling, on the basis
of their association with the BCR upon activation [32],
their kinetics of activation [33], and the presence of tyro-
sine-containing sequences in the cytoplasmic domains of
Igα and Igβ that resemble motifs for phosphorylation by
Src family kinases [34,35]. Consistent with a signal-initiat-
ing role for Lyn in BCR signaling, lyn–/– B cells have
decreased or delayed tyrosine phosphorylations of specific
substrates involved in BCR signaling [25,27,36], as well as
a slight delay in the initiation of their calcium responses to
anti-IgM antibody, as shown in this study (Figure 2). Sur-
prisingly, the major phenotype of lyn–/– B cells was found
to be dramatic hyperproliferative responses and enhanced
MEK1/ERK activation upon anti-IgM antibody treatment,
suggesting that Lyn has a unique role among Src family
kinases in downregulating B cell responses to antigenic
stimulation [24,25]. Here, we extended these studies and
found that the BCR-induced activation of JNK1/2 and
transmembrane calcium influx were also enhanced in
lyn–/– B cells. 
In order to understand the molecular basis of the defective
downregulation of BCR signaling in lyn–/– B cells, we first
examined the FcγRIIb1 pathway. Blocking FcγRIIb1
using the 2.4G2 antibody enhanced the proliferation
Research Paper  Lyn in negative regulation of BCR signaling  Chan et al. 549
Figure 4
Effects of anti-FcγRIIb1 and anti-CD22 antibodies on BCR-induced
calcium response. (a,b) Untreated or 2.4G2 pretreated B cells from 
(a) wild-type or (b) lyn–/– mice were Fluo-3-loaded and stimulated with
rabbit anti-IgM antibody at 12 µg/ml. (c–f) Fluo-3-loaded wild-type and
lyn–/– B cells with or without a 30 min pretreatment with anti-CD22
antibody (2D6) were either super-crosslinked with a secondary
antibody (2°) to the anti-CD22 antibody or mock-treated with media (–)
at 60 sec, as indicated by the first arrow. This was followed by the
addition of anti-IgM F(ab′)2 antibody fragments to a final concentration
of (c,d) 4 µg/ml or (e,f) 2 µg/ml at 240 sec, as indicated by the second
arrow. The calcium responses were analyzed by flow cytometry. The
calcium responses to 2 µM calcium ionophore A23187 are shown in
(e,f) to demonstrate equal Fluo-3 loading. The results are
representative of three or more independent experiments.
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induced by intact goat anti-IgM antibody in wild-type B
cells but not in lyn–/– B cells, suggesting that FcγRIIb1
function is impaired in the absence of Lyn [25]. However,
the 2.4G2 antibody was able to enhance the calcium
response (Figure 4b), ERK2 activation and proliferative
response [25] of lyn–/– B cells to intact rabbit anti-IgM anti-
body, which binds more strongly to FcγRIIb1 than does
goat anti-IgM antibody. It therefore appears that
FcγRIIb1 is at least partially functional in the absence of
Lyn, which corresponds to a partial impairment of
FcγRIIb1 tyrosine phosphorylation in lyn–/– B cells upon
co-ligation with the BCR by intact rabbit anti-IgM anti-
body. A probable explanation is that the phosphorylation
of FcγRIIb1 can be carried out by kinases other than Lyn,
although less efficiently.
In contrast to FcγRIIb1 phosphorylation, we observed a
drastic reduction of CD22 phosphorylation in lyn–/– B cells,
suggesting that Lyn is uniquely required for most of the
basal and BCR-induced phosphorylation of CD22. The
cytoplasmic domain of murine CD22 contains six tyrosine
residues, four of which are predicted to be good substrates
for Src family kinases [34,35] due to the presence of a
leucine or isoleucine residue at the +3 position (number-
ing onwards from the tyrosine residue) [37]. The basal and
BCR-induced phosphorylation of CD22 was normal in B
cells lacking the expression of Fyn, another Src family
kinase expressed in B cells (data not shown). Perhaps the
unique requirement for Lyn to phosphorylate CD22 effi-
ciently relates to the association between Lyn and the
cytoplasmic region of CD22 [14].
The reduction in CD22 phosphorylation in lyn–/– B cells
correlates with an impairment of CD22-mediated negative
regulation of the BCR-induced calcium elevation.
Whereas in wild-type B cells, cross-linking of CD22 (prob-
ably causing its sequestration from the BCR) enhanced
BCR-induced calcium elevation, this treatment did not
affect calcium elevation in lyn–/– B cells (Figure 4c–f). This
result suggests that Lyn is responsible for the phosphory-
lation of one or more tyrosine residues in CD22 that is/are
critical for its ability to regulate the calcium pathway in a
negative manner. Whilst this manuscript was under
review, Smith et al. [38] also reported enhanced calcium
responses and decreased CD22 phosphorylation in
response to BCR stimulation of lyn–/– B cells. The
enhanced calcium responses in lyn–/– B cells were depen-
dent on the presence of extracellular calcium (Figure 2f)
and a similar observation was also made in CD22–/– B cells
[21,39]. It is interesting to note that in addition to the
exaggerated calcium response in B cells, lyn–/– and CD22–/–
mice both have an increased rate of B cell turnover,
reduced numbers of HSAloB220hi B cells and elevated
levels of serum Ig (Figure 2; [18–21,25–27]). Taken
together, these results suggest that the negative effects of
Lyn on BCR-induced calcium elevation are likely to be
mediated by the tyrosine phosphorylation of CD22 and
engagement of the inhibitory functions of CD22. 
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Figure 5
Preligation of CD22 enhances BCR-induced
activation of ERK2 and JNK pathways in both
wild-type and lyn–/– B cells. Purified splenic B
cells were incubated with media alone or with
rat anti-CD22 antibody (2D6) at 15 µg per 107
cells in 1 ml media at room temperature for
30 min. Cells were washed and equilibrated at
37°C for 10 min. Goat F(ab′)2 fragments
against rat IgG (2°) were subsequently added
to the indicated samples and incubated at
37°C for 3 min before stimulation with goat
F(ab′)2 fragments against mouse IgM for
10 min. (a) ERK2 and (b) JNK1/2 were
immunoprecipitated by specific antibodies and
their activities assayed by in vitro kinase assays
using GST–Elk-1 and GST–c-Jun as substrates
respectively. The kinase reactions were
resolved by SDS–PAGE and transferred to
nitrocellulose. The levels of 32P incorporation
were quantitated using a PhosphorImager and
represented as relative activity with respect to
the unstimulated wild-type sample. The
nitrocellulose filters were also immunoblotted
for the respective kinases to verify equivalent
loading. ERK2* represents the active form of
ERK2. Note that the relative ERK2 activity in the
last lane is atypically high in this experiment and
was around the same level as stimulation with
anti-IgM antibody alone in other experiments.
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One surprising result from these studies is that despite the
dramatic reduction of tyrosine phosphorylation on CD22
in lyn–/– B cells, some negative regulation of the ERK2 and
JNK pathways by CD22 was still evident in lyn–/– B cells.
As CD22 phosphorylation did increase slightly upon stim-
ulation of lyn–/– B cells with anti-IgM antibodies, it is pos-
sible that those sites phosphorylated independently of
Lyn are sufficient to mediate at least partial negative regu-
lation of the ERK2 and JNK pathways. Alternatively, it is
also possible that the ability of CD22 to regulate these
kinase pathways does not rely upon tyrosine phosphoryla-
tion of CD22. Some anti-CD22 monoclonal antibodies
have been shown to induce or enhance B cell proliferation
[23,40] and those results were interpreted as a positive
signal being sent by cross-linked CD22. It should be
noted, however, that the rat anti-CD22 antibody used to
cross-link CD22 in our experiments induced negligible
proliferation of wild-type or lyn–/– B cells, even with the
addition of secondary cross-linking antibodies (data not
shown). Thus, the enhanced responses that we observed
with this anti-CD22 antibody more likely reflect the
sequestration of CD22 and prevention of its inhibitory
function, rather than the generation of positive signals
triggered by cross-linking of CD22. Nonetheless, it is clear
that the ability of CD22 to regulate BCR-induced calcium
elevation and BCR-induced activation of ERK2 and JNK
are mechanistically distinct, as only the former is critically
dependent on Lyn. 
It is interesting to note that the levels of ERK2 and JNK
activation (Figure 5, Table 1), as well as those of calcium
mobilization (Figure 4), induced by anti-IgM F(ab′)2 anti-
body fragments in anti-CD22-pretreated lyn–/– B cells
were still higher than the levels induced in similarly
treated wild-type B cells. This could reflect an incomplete
ability of anti-CD22 antibodies to remove the inhibitory
effect of CD22. Another possibility is that negative regula-
tory mechanisms, other than those involving FcγRIIb1
and CD22, may also be defective in the absence of Lyn.
Conclusions
The hyperproliferative response to BCR signaling in lyn–/–
B cells correlates with hyperactivation of the ERK2 and
JNK pathways and elevated calcium responses, suggesting
an inhibitory role for Lyn in BCR signaling. One of the
mechanisms by which Lyn downregulates the BCR signal
is probably mediated by its phosphorylation of CD22. Our
data indicate that Lyn is required for CD22 to inhibit the
BCR-induced calcium response, but not for it to inhibit
the induced activation of ERK and JNK. In contrast, many
of the FcγRIIb1-mediated inhibitory functions appear to
be at least partially functional in lyn–/– B cells. Functional
defects in the ability of CD22, and possibly other regula-
tory pathways, to inhibit BCR signaling contribute to the
hyperresponsiveness of lyn–/– B cells and may be the
underlying reason for the development of autoimmunity
observed in lyn–/– mice. 
Materials and methods
Cells
All experiments were carried out with cells isolated from 6–11-week-
old mice. All the mice used had no evidence of splenomegaly. Purified
splenic B lymphocytes were prepared as previously described [25]. 
Antibodies and other reagents
Rabbit antiserum against GST–CD22 used for CD22 immunoblotting
was a generous gift from Mary-Ann Campbell [16]. Affinity-purified
anti-Lyn antibody [41] and anti-Syk antiserum [42] were described pre-
viously. Except where noted otherwise, the anti-CD22 antibody used in
the CD22 pretreatment experiments was the rat monoclonal anti-
CD22 antibody, 2D6, from Southern Biotechnology. Goat F(ab′)2 frag-
ments against mouse IgM (Fc-specific), intact rabbit anti-mouse IgM,
goat F(ab′)2 fragments against rat IgG (Fc-specific) and goat F(ab′)2
fragments against mouse IgG (Fc-specific) were obtained from
Jackson Immunological Research. The latter two reagents were used
as secondary cross-linking antibodies for the rat anti-CD22 antibody
2D6 and mouse anti-CD22 antibody CY34.1, respectively. Cultured
supernatants were generated from hybridomas (2.4G2, anti-FcγRII;
CY34.1, anti-CD22) obtained from ATCC. Rabbit polyclonal anti-
ERK2 (C-14), anti-JNK1 and anti-JNK2 were obtained from Santa Cruz
Biotechnology. FITC-conjugated anti-mouse IgG1, FITC-conjugated
anti-rat IgG2b, PE-conjugated RA3-6B2 (anti-B220), PE-conjugated
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Table 1
Summary of ERK2 and JNK1/2 activation.
ERK2 activity:
Wild type lyn–/–
2°+ CD22+2°+ Fold 2°+ CD22+2°+ Fold
anti-IgM anti-IgM increase anti-IgM anti-IgM increase 
Expt 1 3.0 10.9 3.6 10.2 20.0 2.0
Expt 2 13.8 20.7 1.5 38.9 47.6 1.2
Expt 3 6.1 29.7 4.9 25.3 52.2 2.1
Expt 4 3.8 6.3 1.7 11.3 13.7 1.2
Expt 5 4.5 7.6 1.7 18.6 23.4 1.3
JNK1/2 activity: 
Wild type lyn–/–
2°+ CD22+2°+ Fold 2°+ CD22+2°+ Fold
anti-IgM anti-IgM increase anti-IgM anti-IgM increase 
Expt 1 2.5 11.0 4.4 8.5 12.2 1.4
Expt 2 2.0 3.4 1.7 4.8 5.9 1.2
Expt 3 2.4 8.8 3.7 8.8 15.9 1.8
Expt 4 1.3 2.1 1.6 1.7 2.6 1.5
Expt 5 2.1 3.8 1.9 6.4 7.6 1.2
Summary of ERK2 and JNK1/2 activation by anti-IgM antibody in the
presence or absence of pretreatment of wild-type and lyn–/– B cells
with anti-CD22 antibody. Five independent experiments were carried
out as described in the legend to Figure 5. In experiments 1 and 2, the
CY34.1 mouse monoclonal anti-CD22 antibody was used, whereas in
experiments 3–5, the 2D6 rat monoclonal anti-CD22 antibody was
used for anti-CD22 antibody pretreatment. In vitro kinase activities of
ERK2 and JNK1/2 in wild-type and lyn–/– B cells were normalized
within each experiment to the unstimulated wild-type sample and
represented as relative activities.
anti-CD11b, PE-conjugated anti-CD4 and PE-conjugated anti-CD8
were obtained from Pharmingen. Propidium iodide was from Cal-
biochem. Except where indicated, cell culture medium used for B cell
purification, incubation and stimulation was RPMI 1640 supplemented
with 5% FCS (Gibco/BRL), 2 mM pyruvate, 2 mM glutamine and
50 µM 2-mercaptoethanol. 
Flow cytometric analysis
Analysis was performed on a FACScan (Becton Dickinson) and the
data acquired to a Macintosh 7300 running CellQuest v3.1 software.
Calcium analysis
Splenocytes (depleted of RBCs) were incubated at 107 per ml culture
medium (see above) plus 10 mM HEPES with 3 µM Fluo-3 AM (Mole-
cular Probes) at 37°C for 30 min. Cells were washed and stained with
PE-conjugated anti-CD11b, anti-CD4 and anti-CD8 antibodies along
with 1 µg/ml propidium iodide for 30 min at room temperature. In
experiments involving pretreatment with 2.4G2 (anti-FcγRII) or rat anti-
CD22 (Southern Biotechnology) antibodies, hybridoma supernatant or
antibodies were added along with the PE-conjugated antibodies
during the same incubation step. Cells were subsequently washed
and resuspended at 5 × 106 per ml culture medium containing 10 mM
HEPES at 37°C. To super-crosslink CD22, F(ab′)2 anti-rat IgG was
added to a final concentration of 10 µg/ml 3 min before anti-IgM anti-
body stimulations. Fluo-3 fluorescence of viable cells (based on pro-
pidium iodide exclusion) in the lymphocyte size gate (based on
forward and side scattering properties) that were CD11b–CD4–CD8–
was analyzed by flow cytometry. Results were plotted as the mean
Fluo-3 fluorescence at 20 sec intervals. In each experiment, wild-type
and lyn–/– cells were also stimulated with 2 µM calcium ionophore
A23187 (Calbiochem) to verify equivalent Fluo-3 loading in both cell
types. In experiments in which cells were stimulated in the presence of
EGTA, EGTA was added to a final concentration of 1 mM immediately
before flow cytometric analysis and cells were stimulated within 3 min
of EGTA addition.
In vitro kinase assays
ERK2 activity was assayed using GST–Elk-1 as a substrate as previ-
ously described [25]. The same buffer system and reaction condi-
tions were used to assay for JNK except that GST–c-Jun(1–79) [43]
was used as a substrate for JNK. Antibodies that recognize both
JNK1 and JNK2 were used to immunoprecipitate JNK from lysates.
The kinase reactions were resolved either on 10% low-bis gels
(SDS–polyacrylamide gels containing an acrylamide:bis-acrylamide
ratio of 120:1) for ERK2 or on 10% regular gels (acrylamide:bis-acry-
lamide ratio of 37.5:1) for JNK. The proteins in the resolving gels
were transferred to nitrocellulose. After exposure to film and to Phos-
phorImager screens (Molecular Dynamics) for quantitation, the nitro-
cellulose membranes were immunoblotted for the respective kinases
to verify equivalent loading.
Immunoprecipitations and immunoblotting
Preparation of cell lysates, protein quantitation, immunoprecipitations
and immunoblotting were performed as previously described [25].
FcγRIIb1 was immunoprecipitated by 2.4G2 antibodies that were cova-
lently coupled to protein-G–Sepharose beads using 20 mM
dimethylpimelimidate (Pierce). 
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